Fulcher G - Search Results

1

Efficacy of biphasic insulin aspart in patients with type 2 diabetes.

Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G. Halimi S, et al. Among authors: fulcher g. Clin Ther. 2005;27 Suppl B:S57-74. doi: 10.1016/j.clinthera.2005.11.021. Clin Ther. 2005. PMID: 16519038 Review.

2

Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring.

Hay LC, Wilmshurst EG, Fulcher G. Hay LC, et al. Among authors: fulcher g. Diabetes Technol Ther. 2003;5(1):19-26. doi: 10.1089/152091503763816427. Diabetes Technol Ther. 2003. PMID: 12725703

3

Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.

Fulcher GR, Gilbert RE, Yue DK. Fulcher GR, et al. Intern Med J. 2005 Sep;35(9):536-42. doi: 10.1111/j.1445-5994.2005.00902.x. Intern Med J. 2005. PMID: 16105155 Clinical Trial.

4

Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.

Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, Gylvin T, Kawamori R. Davidson JA, et al. Among authors: fulcher g. Clin Ther. 2009 Aug;31(8):1641-51. doi: 10.1016/j.clinthera.2009.08.011. Clin Ther. 2009. PMID: 19808125

5

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.

Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C. Zinman B, et al. Among authors: fulcher g. Lancet. 2011 Mar 12;377(9769):924-31. doi: 10.1016/S0140-6736(10)62305-7. Lancet. 2011. PMID: 21396703 Clinical Trial.

6

Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial.

van Dieren S, Kengne AP, Chalmers J, Beulens JW, Davis TM, Fulcher G, Heller SR, Patel A, Colagiuri S, Hamet P, Mancia G, Marre M, Neal B, Williams B, Peelen LM, van der Schouw YT, Woodward M, Zoungas S. van Dieren S, et al. Among authors: fulcher g. Diabetes Obes Metab. 2014 May;16(5):426-32. doi: 10.1111/dom.12238. Epub 2013 Dec 16. Diabetes Obes Metab. 2014. PMID: 24251579 Clinical Trial.

7

Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.

Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH, Niskanen LK; BOOST: Intensify Premix I Investigators. Fulcher GR, et al. Diabetes Care. 2014 Aug;37(8):2084-90. doi: 10.2337/dc13-2908. Epub 2014 May 8. Diabetes Care. 2014. PMID: 24812432 Clinical Trial.

8

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.

Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, Jiang J, Vercruysse F, Meininger G, Matthews D; CANVAS Trial Collaborative Group. Neal B, et al. Among authors: fulcher g. Diabetes Care. 2015 Mar;38(3):403-11. doi: 10.2337/dc14-1237. Epub 2014 Dec 2. Diabetes Care. 2015. PMID: 25468945 Clinical Trial.

9

What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres.

Fulcher G, Roberts A, Sinha A, Proietto J. Fulcher G, et al. Diabetes Res Clin Pract. 2015 Jun;108(3):405-13. doi: 10.1016/j.diabres.2015.03.004. Epub 2015 Mar 14. Diabetes Res Clin Pract. 2015. PMID: 25887419

10

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.

Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, Woo V, Wysham C, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B; CANVAS trial collaborative group. Fulcher G, et al. Diabetes Obes Metab. 2016 Jan;18(1):82-91. doi: 10.1111/dom.12589. Epub 2015 Dec 8. Diabetes Obes Metab. 2016. PMID: 26450639 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results